Morgan Stanley
CRSP icon

Morgan Stanley’s CRISPR Therapeutics CRSP Stock Holding History

Morgan Stanley’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48M Buy
879,949
+211,807
+32% +$11.2M ﹤0.01% 2271
2026
Q1 		$31.8M Buy
668,142
+1,082
+0.2% +$57.1K ﹤0.01% 2531
2025
Q4 		$35M Sell
667,060
-730,799
-52% -$43.8M ﹤0.01% 2424
2025
Q3 		$90.6M Buy
1,397,859
+886,479
+173% +$50.9M 0.01% 1483
2025
Q2 		$24.9M Sell
511,380
-788,602
-61% -$30.5M ﹤0.01% 2588
2025
Q1 		$44.2M Buy
1,299,982
+804,980
+163% +$34.1M ﹤0.01% 1923
2024
Q4 		$19.5M Sell
495,002
-137,001
-22% -$6.47M ﹤0.01% 2772
2024
Q3 		$29.7M Buy
632,003
+34,324
+6% +$1.74M ﹤0.01% 2390
2024
Q2 		$32.3M Sell
597,679
-488,245
-45% -$28.2M ﹤0.01% 2162
2024
Q1 		$74M Buy
1,085,924
+259,770
+31% +$18.6M 0.01% 1405
2023
Q4 		$51.7M Buy
826,154
+474,719
+135% +$26.2M ﹤0.01% 2415
2023
Q3 		$16M Sell
351,435
-39,405
-10% -$2.04M ﹤0.01% 2688
2023
Q2 		$21.9M Sell
390,840
-79,686
-17% -$4.52M ﹤0.01% 2386
2023
Q1 		$21.3M Sell
470,526
-37,267
-7% -$1.81M ﹤0.01% 2353
2022
Q4 		$20.6M Sell
507,793
-78,051
-13% -$4.14M ﹤0.01% 2314
2022
Q3 		$38.3M Buy
585,844
+18,386
+3% +$1.33M 0.01% 1535
2022
Q2 		$34.5M Buy
567,458
+50,070
+10% +$2.94M ﹤0.01% 1705
2022
Q1 		$32.5M Sell
517,388
-26,122
-5% -$1.64M ﹤0.01% 1638
2021
Q4 		$41.2M Sell
543,510
-36,511
-6% -$3.19M 0.01% 1489
2021
Q3 		$64.9M Buy
580,021
+60,256
+12% +$7.57M 0.01% 1122
2021
Q2 		$84.1M Sell
519,765
-347,503
-40% -$42.3M 0.01% 956
2021
Q1 		$106M Buy
867,268
+135,841
+19% +$20.5M 0.02% 739
2020
Q4 		$112M Buy
731,427
+227,927
+45% +$26.9M 0.02% 670
2020
Q3 		$42.1M Sell
503,500
-57,813
-10% -$5.13M 0.01% 995
2020
Q2 		$41.3M Sell
561,313
-290,206
-34% -$17M 0.01% 936
2020
Q1 		$36.1M Buy
851,519
+596,255
+234% +$30.8M 0.01% 899
2019
Q4 		$15.5M Sell
255,264
-3,477
-1% -$190K ﹤0.01% 1902
2019
Q3 		$10.6M Sell
258,741
-26,243
-9% -$1.25M ﹤0.01% 2060
2019
Q2 		$13.4M Buy
284,984
+16,361
+6% +$654K ﹤0.01% 1849
2019
Q1 		$9.6M Buy
268,623
+75,437
+39% +$2.61M ﹤0.01% 2078
2018
Q4 		$5.52M Sell
193,186
-39,354
-17% -$1.37M ﹤0.01% 2788
2018
Q3 		$10.3M Buy
232,540
+36,098
+18% +$1.89M ﹤0.01% 2391
2018
Q2 		$11.5M Buy
196,442
+99,822
+103% +$5.69M ﹤0.01% 2208
2018
Q1 		$4.42M Buy
96,620
+7,814
+9% +$323K ﹤0.01% 3156
2017
Q4 		$2.08M Buy
88,806
+50,036
+129% +$951K ﹤0.01% 4000
2017
Q3 		$693K Sell
38,770
-708,952
-95% -$12.9M ﹤0.01% 4674
2017
Q2 		$12M Buy
747,722
+727,196
+3,543% +$12M ﹤0.01% 1999
2017
Q1 		$447K Buy
20,526
+16,710
+438% +$328K ﹤0.01% 4907
2016
Q4 		$77K Buy
+3,816
New +$71.3K ﹤0.01% 5646

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley's CRSP Position: Q2 2026 in Review

Morgan Stanley increased its CRISPR Therapeutics (CRSP) stake by 32% in Q2 2026, buying an estimated $11.2M and bringing the position to 879,949 shares worth $48M. The position accounts for ﹤0.01% of the portfolio, ranked #2271.

Morgan Stanley first reported a position in CRSP in Q4 2016 and has held it in 39 quarters since. The position peaked at $112M in Q4 2020. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Morgan Stanley held 879,949 shares of CRISPR Therapeutics worth $48M as of Q2 2026.
  • Morgan Stanley bought 211,807 CRISPR Therapeutics shares in Q2 2026, an estimated $11.2M.
  • CRISPR Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #2271 holding.
  • Morgan Stanley first reported a position in CRISPR Therapeutics in Q4 2016 and has held it in 39 quarters since.
  • Morgan Stanley's CRISPR Therapeutics position peaked at $112M in Q4 2020.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.